The global retinoblastoma treatment market is anticipated to grow at a significant CAGR during the forecast period. Retinoblastoma is a type of cancer that affects the retina. Although retinoblastoma is a rare disorder, it is still found to be very common eye cancer in children of age below 5 years. According to the National Organization for Rare Disease Disorder (NORD), retinoblastoma is considered to be a leading cause of blindness in children and accounts for almost 3% of all childhood malignancies. Hence, the high prevalence of retinoblastoma will significantly drive the retinoblastoma treatment market.
A full Report of Global Retinoblastoma Treatment Market is Available at https://www.omrglobal.com/industry-reports/retinoblastoma-treatment-market
The treatment of retinoblastoma includes various drug delivery and chemotherapy techniques which can provide some timely benefits. Surgery in retinoblastoma is expected to be a permanent treatment option as it removes the tumor completely from the retina. Therefore, the adoption of surgery will rise considering its permanent benefits, in turn driving the retinoblastoma treatment industry considerably during the forecast period.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/retinoblastoma-treatment-market
Additionally, the use of chemotherapy in the retinoblastoma treatment market is also anticipated to rise in recent times owing to the presence of various chemotherapy approaches. For instance, intraarterial chemotherapy is one such chemotherapy approach that involves a surgical procedure. However, the side effects associated with chemotherapy such as transfusions, infected ports, fevers, neutropenia, and many more will restrict the growth of chemotherapy in the retinoblastoma treatment market.
Moreover, various other side-effects were also observed in the treatment of retinoblastoma treatment including vision loss in the long-term that eventually lead to the removal of the eye. This is anticipated to significantly lower the growth rate of the retinoblastoma treatment market during the forecast period. Therefore, new therapeutic strategies are being considered for the retinoblastoma treatment that is more efficient and has less associated side effects which will drive the market growth.
Besides the side effects of retinoblastoma treatment, the survival rate of patients with this condition is also considerably high that is up to 95% if it was not spread to any other body part. Hence, the high survival rate will drive the adoption of treatment, in turn, fuelling the growth of the retinoblastoma treatment market during the forecast period.
Global Retinoblastoma Treatment Market- Segmentation
By Treatment Type
• Radiation therapy
• Laser Therapy (Photocoagulation)
By Type of Retinoblastoma
• Non-hereditary Retinoblastoma
• Hereditary Retinoblastoma
Global Retinoblastoma Treatment Market- Segment by Region
• Rest of Europe
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East and Africa
• AbbVie Inc.
• Accuray Incorporated
• Baxter International Inc.
• Bristol-Myers Squibb Co.
• Cadila Pharmaceuticals Ltd.
• CryoConcepts LP.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson Services, Inc.
• Merck & Co. Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/retinoblastoma-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visithttps://www.omrglobal.com
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404